Age and dose sensitivities in the 2-butoxyethanol F344 rat model of hemolytic anemia and disseminated thrombosis.

Hadassah Medical Center, Hebrew University, Jerusalem, Israel.
Experimental and Toxicologic Pathology (Impact Factor: 2.01). 04/2007; 58(5):311-22. DOI: 10.1016/j.etp.2006.11.003
Source: PubMed

ABSTRACT In hemolytic disorders, such as sickle cell disease and beta-thalassemia, the mechanisms of thrombosis are poorly understood. Appropriate animal models would increase the understanding of the pathophysiology of thrombosis. We previously reported that rats exposed to 2-butoxyethanol (2-BE) developed hemolytic anemia and disseminated thrombosis resembling sickle cell disease and beta-thalassemia. To characterize our model further, we investigated age- and dose-related differences in sensitivity to 2-BE. We exposed groups of 6- and 12-week-old F344 rats (5 animals/group) to 62.5, 125, and 250 mg/kg/day of 2-BE for up to 4 days. Blood was collected on days 2-4 for complete blood count and measurement of intracellular adhesion molecule-1 (ICAM-1). Histopathological evaluation was performed to find evidence of disseminated thrombosis. The maximum hemolytic response, resulting in decreased erythrocyte count and higher mean cell volume (MCV) occurred in the 12-week-old rats treated with the highest dose of 2-BE (250 mg/kg, p<0.0001). The highest increase in ICAM-1 levels occurred in the 12-week-old rats treated with 125 and 250 mg/kg 2-BE (p<0.0001). No intravascular thrombi were noted in the 6-week-old 2-BE-treated animals. The majority of intravascular thrombi occurred in the 12-week-old rats treated with 250 mg/kg 2-BE. Because our findings show age- and dose-related sensitivities, we suggest that 12-week-old rats and doses of 250 mg/kg be used in the 2-BE model.

  • [Show abstract] [Hide abstract]
    ABSTRACT: With the progressive aging of the population surgical candidates have more comorbidities resulting in a higher risk to develop postoperative complications. One of the most frequent postoperative complications in the elderly is acute confusional state or delirium, which may have devastating consequences: higher mortality, and risk of medical complications during admission and, a higher risk of functional decline, institutionalization, and cognitive impairment at discharge. For all these reasons and with the aim of optimising surgical procedures, it is essential to identify patients at risk of delirium in order to take appropriate preventive action and provide early treatment. In the present article we review the current evidence on the management of postoperative delirium in the elderly.
    Cirugía Española 12/2011; 90(2):75-84. · 0.87 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Abnormality in hematological condition including hemolytic disorders has been suggested one of the risk factor of pulmonary thrombosis. We previously reported that phenylhydrazine (PHZ) could induce acute thrombosis in the rat lung. In this study, time-related hematological and histopathological changes were evaluated in PHZ-treated rats to reveal the pathogenesis of pulmonary thrombosis in hemolytic condition. Male Sprague-Dawley rats were administered PHZ at 40mg/kg/day daily for up to 4 days (n=6). At 24h after the last administration (i.e. on days 1, 2, 3, or 4), animals were euthanized and samples were subjected to hematology, light microscopy, and electron microscopy. PHZ-treated rats developed severe anemia on day 1 or later. On day 2 and after, congestion in the alveolar septa corresponding to accumulation of deformed/ghost erythrocytes in the alveolar capillaries was observed, which was the earliest change that preceded thrombus formation. Focal fibrin deposition in the alveolar septa was noted on day 3 and it expanded widely by day 4, while endothelial injury were minimally noted just on day 4. These congestive/thrombotic changes were predominant in the pulmonary capillaries. Changes in hemostatic parameters were noted only on day 4; which were prolonged prothrombin time and activated partial thromboplastin time, greatly increased plasma thrombin-antithrombin complex levels with statistical significance, and slightly decreased fibrinogen levels. In conclusion, the trigger of acute pulmonary thrombosis in PHZ-treated rats was considered to be regional stasis resulting from blockage caused by the deformed erythrocytes, and subsequent systemic hemostatic disruption.
    Experimental and toxicologic pathology: official journal of the Gesellschaft fur Toxikologische Pathologie 03/2012; · 1.43 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Wistar rats are frequently used in toxicologic studies; however, the impact of animal source on hematologic reference intervals (RI) is not known. The purpose of this study was to compare hematologic data of Wistar rats obtained from 2 breeders and to calculate preliminary RI for the Sysmex XT-2000iV hematology analyzer. Blood collected in EDTA from 75 10-13-week-old rats (male, n = 38; female, n = 37) from breeder 1 and 60 rats (male, n = 30; female, n = 30) from breeder 2 was analyzed using a Sysmex XT-2000iV hematology analyzer. Results were analyzed for differences using a t-test or Mann-Whitney U-test. Sex-specific 95% RI were calculated for rats from both breeders. Significant breeder-specific differences were found for WBC, RBC, platelet, lymphocyte, monocyte, eosinophil, and reticulocyte counts and MCV, MCH, MPV, and plateletcrit for both sexes, and for HCT and hemoglobin concentration for female rats. The greatest differences (P < .0001) between rats from breeders 1 and 2, respectively, were found for WBC (female: 2.2-5.9 × 10(9) /L vs 4.2-9.4 × 10(9) /L 38; male: 3.4-9.5 vs 6.4-14.4 × 10(9) /L), lymphocyte (female: 1.7-4.8 × 10(9) /L vs 3.4-8.2 × 10(9) /L; male: 2.6-7.8 vs 5.2-12.4 × 10(9) /L), and platelet (female: 591-836 × 10(9) /L vs 804-1282 × 10(9) /L; male: 573-998 × 10(9) /L vs 861-1247 × 10(9) /L) counts. Differences in hematologic RI between Wistar rats obtained from different breeders underscore the need to evaluate untreated control animals for comparison, rather than using historical RI, to detect compound-related effects in preclinical safety studies. Valid RI for control animals are needed and should be verified when using a new supplier to avoid misinterpretation of data. Low reference limits for some variables, such as WBC counts, in rats from one source may preclude their use in studies in which detection of leukopenia is required.
    Veterinary Clinical Pathology 05/2012; 41(2):228-34. · 1.29 Impact Factor

Full-text (2 Sources)

Available from
May 22, 2014